Coronary Artery Disease and Coronary Microvascular Disease in Cardiomyopathies Registry

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-100
SponsorUniversity Hospital, Grenoble

About this trial

Long-term prognostic value of macrovascular and microvascular coronary artery stenoses in each type of cardiomyopathy.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Ischemic

Dilated

Hypertrophic

Restrictive cardiomyopathy.

Disqualifiers

Pregnant women

Breastfeeding women

Patients under legal protection

Trial population

Patients with a cardiomyopathy

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Patients with a cardiomyopathy

    Other intervention

    Prognostic value of coronary artery disease and microvascular disease in the different types of cardiomyopathies.

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

1

Major Adverse Cardiovascular Events

Composite outcome = rate of cardiovascular death, non-fatal myocardial infarction, need for myocardial revascularization by coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI) \> 3 months after enrollment. During follow up

Time frame
5 years

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University Hospital, Grenoble

Lead sponsor

Clinique Belledonne

Collaborator

Groupe Hospitalier Mutualiste de Grenoble

Collaborator

Centre Hospitalier Annecy Genevois

Collaborator

Centre Hospitalier Metropole Savoie

Collaborator